Home › Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment
 

Keywords :   


Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment

2015-11-20 04:25:37| drugdiscoveryonline Home Page

Gurnet Point Capital, an investment firm focused on the healthcare and life sciences sectors that was founded by Ernesto Bertarelli and is led by Christopher A. Viehbacher, recently announced the creation of Boston Pharmaceuticals, a fully-integrated drug development company that will offer an innovative alternative model for drug development and commercialization.

Tags: company point development capital

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.12South Western Railway to be renationalised by Labour
03.12Labelexpo South China 2024 features latest industry trends
03.12PPG Earns Two Awards During CARES 2024 Automotive Forums in U.S., Europe
03.12Filtrex 2025 to be Held in March
03.12Nu-Maber Italy adds dual ThermoFlexX Catena-E 80 units
03.12TEKLYNX assists with label compliance
03.12Megnajet supporting Arrow Systems\' growing digital portfolio
03.12WEG Achieves Gold Certification in EcoVadis for Second Consecutive Year
More »